Antibiotic Access Crisis Fuels Superbug Surge in India

Mon Oct 20 2025 06:27:39 GMT+0300 (Eastern European Summer Time)

A new study reveals a devastating imbalance in India's antibiotic access and usage, as superbugs thrive while patients suffer without necessary treatments.

As antibiotic resistance rises sharply in India, a recent study highlights the struggle for patients to access life-saving medications. While rampant misuse of antibiotics contributes to the rise of resistant strains, many afflicted individuals lack even basic access to the drugs they need.

India faces a severe crisis as antibiotic-resistant superbugs proliferate, exacerbated by restricted access to critical medications. A study from the Global Antibiotic Research and Development Partnership (GARDP) underscores the troubling paradox: while antibiotics are often overprescribed, many patients with superbug infections are unable to obtain the needed treatments.

The research, published in The Lancet Infectious Diseases, examined nearly 1.5 million cases of carbapenem-resistant Gram-negative (CRGN) bacteria across major low- and middle-income countries, including India, Brazil, and South Africa. Findings indicated that only a dismal 6.9% of affected patients received proper treatment. Alarmingly, India accounted for 80% of the infections necessitating treatments, yet only managed to provide antibiotic courses for 7.8% of the cases.

Carbapenem-resistant Gram-negative bacteria are notorious for causing severe infections, such as urinary tract infections and pneumonia, particularly threatening vulnerable groups, including newborns, the elderly, and hospital patients with weakened immune systems.

Dr. Abdul Gaffar, an infectious disease consultant at Apollo Hospital in Chennai, highlighted the dire situation, stating, "We often see patients for whom no antibiotic works - and they die." Meanwhile, Dr. Jennifer Cohn, GARDP's Global Access Director, emphasizes that while global dialogues focus on curbing antibiotic overuse, many individuals in poorer nations perish due to a lack of access to necessary medications.

Among the eight intravenous antibiotics analyzed, Tigecycline emerged as the most utilized, despite the study revealing that only a fraction—103,647 treatment courses—was procured, compared to the 1.5 million patients who required them. The primary barriers to accessing effective treatments include inadequate healthcare infrastructure, high costs, and limited diagnostic capabilities.

The growing disparity means that affluent patients tend to misuse antibiotics while poorer individuals remain untreated. Dr. Gaffar advocates for improved affordability and regulatory measures, suggesting that all antibiotic prescriptions should require additional oversight from specialists.

Experts argue that India’s strong pharmaceutical industry, combined with its urgent need for innovation in antibiotic research and development, could provide a significant role in addressing antimicrobial resistance globally. With the right policies, local data gathering, and innovative healthcare models, India may lead the charge in both improving access to antibiotics and safeguarding them for essential use.

Without decisive action, medical advancements risk unraveling, as antibiotic access remains critical for safely conducting surgeries, managing cancer care, and treating everyday illnesses.